Minerva Neurosciences Price To Sales Ratio Over Time

NERV Stock  USD 2.26  0.11  5.12%   
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Minerva Neurosciences Performance and Minerva Neurosciences Correlation.
For more information on how to buy Minerva Stock please use our How to Invest in Minerva Neurosciences guide.
  
Price To Sales Ratio is likely to drop to 1.86 in 2024.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Minerva Neurosciences. If investors know Minerva will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Minerva Neurosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.45)
Return On Assets
(0.29)
Return On Equity
(6.75)
The market value of Minerva Neurosciences is measured differently than its book value, which is the value of Minerva that is recorded on the company's balance sheet. Investors also form their own opinion of Minerva Neurosciences' value that differs from its market value or its book value, called intrinsic value, which is Minerva Neurosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Minerva Neurosciences' market value can be influenced by many factors that don't directly affect Minerva Neurosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Minerva Neurosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Minerva Neurosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Minerva Neurosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Specify up to 10 symbols:

Cross Equities Price To Sales Ratio Analysis

Compare Minerva Neurosciences and related stocks such as Reviva Pharmaceuticals, Eyenovia, and Cognition Therapeutics Price To Sales Ratio Over Time
Select Fundamental
Price To Sales RatioDividend Yield
Ptb RatioDays Sales Outstanding
Book Value Per ShareFree Cash Flow Yield
Invested CapitalOperating Cash Flow Per Share
Average PayablesStock Based Compensation To Revenue
Capex To DepreciationPb Ratio
Ev To SalesFree Cash Flow Per Share
RoicInventory Turnover
Net Income Per ShareDays Of Inventory On Hand
Payables TurnoverSales General And Administrative To Revenue
Average InventoryResearch And Ddevelopement To Revenue
Capex To RevenueCash Per Share
PocfratioInterest Coverage
Payout RatioCapex To Operating Cash Flow
Pfcf RatioDays Payables Outstanding
Net Current Asset ValueIncome Quality
RoeTangible Asset Value
Ev To Operating Cash FlowPe Ratio
Return On Tangible AssetsEv To Free Cash Flow
Earnings YieldIntangibles To Total Assets
Net Debt To E B I T D ACurrent Ratio
Tangible Book Value Per ShareReceivables Turnover
Graham NumberShareholders Equity Per Share
Debt To EquityCapex Per Share
Graham Net NetAverage Receivables
Revenue Per ShareInterest Debt Per Share
Debt To AssetsEnterprise Value Over E B I T D A
Short Term Coverage RatiosPrice Earnings Ratio
Price Book Value RatioPrice Earnings To Growth Ratio
Days Of Payables OutstandingDividend Payout Ratio
Price To Operating Cash Flows RatioPrice To Free Cash Flows Ratio
Pretax Profit MarginEbt Per Ebit
Operating Profit MarginEffective Tax Rate
Company Equity MultiplierLong Term Debt To Capitalization
Total Debt To CapitalizationReturn On Capital Employed
Debt Equity RatioEbit Per Revenue
Quick RatioDividend Paid And Capex Coverage Ratio
Net Income Per E B TCash Ratio
Operating Cash Flow Sales RatioDays Of Inventory Outstanding
Days Of Sales OutstandingFree Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage RatiosPrice To Book Ratio
Fixed Asset TurnoverCapital Expenditure Coverage Ratio
Price Cash Flow RatioEnterprise Value Multiple
Debt RatioCash Flow To Debt Ratio
Price Sales RatioReturn On Assets
Asset TurnoverNet Profit Margin
Gross Profit MarginPrice Fair Value
Return On Equity
201020112012201320142015201620172018201920202021202220232024
RVPHW0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0
EYEN63.795863.795863.795863.795863.795863.795863.795863.795863.795863.795863.79587.521222.5 K20.3 K21.3 K
CGTX0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0
RNAZ0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0
KOD0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0
ZURA0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0
ANNX0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0
INAB0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0
WVE1.1 K1.1 K1.1 K1.1 K1.1 K1.1 K40225184.495316.993615.37693.97261514.72884.49
DAWN0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0
ABOS476476476476476476476476476476562562562506415
XFOR1.82551.82551.82551.82551.82551.82551.82551.82551.825543.031743.031743.031743.031738.7340.66
INZY0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0
ALXO3193193193193193193193193192282.9 K2.9 K2.9 K2.6 K2.7 K
CABA0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0
VIRX24.291638.107418910993.713121.497122.450313663.228314.32645.39665.39665.39666.215.9
EYPT32013.620940.969534.29514.169255.24268.016732.47227.93897.93892.45269.52923.154519.038618.09
BMEA0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0
MREO(101)(101)(101)(101)(101)(101)(101)(101)(1.8 K)(1.8 K)2.3 K17.1116248152101
TERN179179179179179179179179179179179179179161143
LPTX88.991688.991688.991688.991688.991688.991688.991688.991688.991688.991688.9916185185167110

Minerva Neurosciences and related stocks such as Reviva Pharmaceuticals, Eyenovia, and Cognition Therapeutics Price To Sales Ratio description

Price to Sales Ratio is figured by comparing Minerva Neurosciences stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Minerva Neurosciences sales, a figure that is much harder to manipulate than other Minerva Neurosciences multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

My Equities

My Current Equities and Potential Positions

Minerva Neurosciences
NERV
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
LocationMassachusetts; U.S.A
ExchangeNASDAQ Exchange
USD 2.26

Additional Tools for Minerva Stock Analysis

When running Minerva Neurosciences' price analysis, check to measure Minerva Neurosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Minerva Neurosciences is operating at the current time. Most of Minerva Neurosciences' value examination focuses on studying past and present price action to predict the probability of Minerva Neurosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Minerva Neurosciences' price. Additionally, you may evaluate how the addition of Minerva Neurosciences to your portfolios can decrease your overall portfolio volatility.